March 29, 2019
Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
-Phase 2 innovaTV 204 Trial Designed to Support Potential Accelerated Approval Pathway in U.S.- BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN)…